MedTrace Logo

Safety Study of Anti-IgE Immunotherapy in Allergic Patients

NCT00439621 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2008-08-18

No results posted yet for this study

Summary

The purpose of the study is to evaluate safety and efficacy of three doses and two dosing regimens of RP01 as an anti-IgE immunotherapy in allergic patients.

Conditions

  • Allergy

Interventions

BIOLOGICAL

RP 01

Active immunotherapy

Sponsors & Collaborators

  • Resistentia Pharmaceuticals AB

    lead INDUSTRY

Principal Investigators

  • Vidar Wendel-Hansen, MD, PhD · Resistentia Pharmaceuticals AB

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-03-31
Completion
2008-08-31

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439621 on ClinicalTrials.gov